Invasive papillary carcinoma of the breast is a rare, distinct variant comprising approximately less than 1-2% of all newly diagnosed cases of breast carcinoma and is usually found in postmenopausal women with a more favorable prognosis. We report an unusual case in a 45-year-old perimenopausal female who came with a complaint of lump in right breast for duration of 1 year. A simple mastectomy was undertaken for histopathological study and immunohistochemistry (IHC) which showed characteristic features of an invasive papillary breast carcinoma. We present this case in view of its rarity and to highlight this clinicopathological subtype for its good prognosis and to avoid overtreatment.
Background and Objectives: Despite various treatment and diagnostic options, Breast cancer remains one of the top cancer in women both in developed and the developing world. In such a scenario, Immunohistochemistry plays an important role in pathology of breast disease which contributes for solving diagnostic problems and for determining prognosis and response to therapy. There is growing list of IHC markers available, the present study highlights the importance of vimentin a mesenchymal marker in breast carcinoma cases. Objectives of the Study: 1) To assess the expression of vimentin in various types of breast carcinomas.2) To find out the correlation between expression of vimentin and prognostic markers such as tumor size, tumor grade and lymph node status. Materials and Methods: The study included 50 cases of modified radical mastectomy specimens received in the Department of Pathology, during December 2017 to May 2019. After collecting the history, the specimens were examined, fixed in 10% formalin and sections were studied by hematoxylin and eosin and immunohistochemically.Results: In the present study majority of the patients were in the age group of <40 years (Mean age-51 years). Vimentin expression was seen in 23/50 (46%) of cases. Its expression was correlated significantly with high grade tumors (P value<0.05) indicating epithelial to mesenchyamal transition of tumor cells. Majority of the tumors were of grade 2(48%) and diagnosed histopathologically as invasive carcinoma breast NST. Vimentin expression did not correlate with lymph node status and tumor size (P value<0.05). Interpretation and Conclusion:Vimentin is preferentially expressed in high grade tumours. Its expression has no correlation with tumour size and nodal metastasis, which could aid in early treatment and prolonged survival rate among patients independent of other prognostic parameters.
Prostate cancer exhibits a complex genetic and heterogeneous histological pattern reflecting its multifactorial phenotype. Mast cells mainly known for their role in allergy and anaphylaxis, now regarded as key factor cell in angiogenesis, tissue remodeling and repair, whereas their importance in tumor pathology as either cancer promoter or inhibitor is still debated. Materials and Methods: Study included 100 cases of prostatic lesions with 74 cases of benign prostatic lesions and 26 cases of adenocarcinoma prostate, received in the form of transurethral resection of prostate chips for histopathological examination. The tissues were routinely processed, the paraffin sections stained by hematoxylin and eosin and 1% toluidine blue. Histological diagnosis was made. Mast cell count was done taking a standard of 10 high power fields(x40) and mean were calculated. Distributions of mast cells were noted in stroma, perivascular, periglandular and intraglandular regions. Results: Mast cell count was significantly higher in benign prostatic hyperplasia with mean of 3.6 per high power field whereas absence or low count was found in adenocarcinoma prostate with mean of 1.7 per high power field. Mast cells were located predominantly in stromal region in both BPH and adenocarcinoma prostate; in rest of the areas the numbers were comparable. Conclusion: In this study we observed significant increase in mast cell count in stroma of BPH compared to adenocarcinoma indicating that mast cell density is inversely proportional to malignancy. This suggests high mast cell count favors the prognosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.